Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioxytranBIXT -14.72% EV-to-FCF is -5.65 as of Jul. 16, 2026. The stock has 3 warning signs investors should review. Among 334 Biotechnology companies, Bioxytran ranks worse than 299400.9% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bioxytran's Enterprise Value is $3.56 Mil.
Bioxytran's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.63 Mil. Therefore, Bioxytran's EV-to-FCF for today is -5.65.
The historical rank and industry rank for Bioxytran's EV-to-FCF or its related term are showing as below:
BIXT'
s EV-to-FCF Range Over the Past 10 Years
Min: -83.48 Med: 23.46 Max: 10739.88
Current: -5.65
During the past 13 years, the highest EV-to-FCF of Bioxytran was 10739.88. The lowest was -83.48. And the median was 23.46.
BIXT's EV-to-FCF is ranked worse than 100% of 334
companies
in the Biotechnology industry
Industry Median: 15.69
vs BIXT: -5.65
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bioxytran's share price for today is $0.02422.
Bioxytran's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.025.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bioxytran EV-to-FCF Related Terms
Bioxytran EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bioxytran's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bioxytran's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioxytran EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioxytran's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bioxytran's EV-to-FCF falls into.
Bioxytran's current Enterprise Value is $3.56 Mil.
Bioxytran's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioxytran (BIXT) has a EV-to-FCF of -5.65 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioxytran and its competitors. According to the industry distribution chart, Bioxytran ranks #999999 out of 334 companies in the Biotechnology industry.
Is Bioxytran's EV-to-FCF too high?
Bioxytran's current EV-to-FCF is -5.65. Based on the distribution chart, Bioxytran ranks #999999 out of 334 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bioxytran's EV-to-FCF compare to SPRC and ACUT?
According to the Biotechnology industry distribution chart, Bioxytran ranks #999999 out of 334 companies for EV-to-FCF. This places Bioxytran in the lower half of its industry. The industry median EV-to-FCF is 15.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.69, based on 334 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioxytran and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioxytran's current EV-to-FCF is -5.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioxytran stock overvalued right now?
Bioxytran (BIXT) has a current EV-to-FCF of -5.65. The current EV-to-FCF is -5.65. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bioxytran (BIXT), the current EV-to-FCF is -5.65 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioxytran Inc is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. Bioxytran uses Galectin inhibitors to combat the virus, SARS-CoV-2. Glycovirology is a novel glycan-based platform technology. The concept involves using sugar-based drugs to block viruses. The company is developing an inventive platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIXT has been successfully added to your 
